29 Nov 2021 Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000 Investors | Therapeutics
03 Nov 2021 Interview with Fiona McLaughlin – Avacta Chief Scientific Officer, Therapeutics Blogs | Therapeutics
29 Sep 2021 Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership Investors | Therapeutics
06 Sep 2021 Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division Investors | Therapeutics
02 Sep 2021 Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta’s Therapeutics Division Investors | Therapeutics
11 Aug 2021 Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase 1 Clinical Trial Investors | Therapeutics
18 Feb 2021 Phase I Clinical Trial Authorisation for AVA6000 Approved by MHRA Investors | Therapeutics
23 Dec 2020 Submission of Clinical Trial Application for AVA6000 Pro-doxorubixin Investors | Therapeutics